Your browser doesn't support javascript.
loading
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker, Chris C; James, Nicholas D; Brawley, Christopher D; Clarke, Noel W; Ali, Adnan; Amos, Claire L; Attard, Gerhardt; Chowdhury, Simon; Cook, Adrian; Cross, William; Dearnaley, David P; Douis, Hassan; Gilbert, Duncan C; Gilson, Clare; Gillessen, Silke; Hoyle, Alex; Jones, Rob J; Langley, Ruth E; Malik, Zafar I; Mason, Malcolm D; Matheson, David; Millman, Robin; Rauchenberger, Mary; Rush, Hannah; Russell, J Martin; Sweeney, Hannah; Bahl, Amit; Birtle, Alison; Capaldi, Lisa; Din, Omar; Ford, Daniel; Gale, Joanna; Henry, Ann; Hoskin, Peter; Kagzi, Mohammed; Lydon, Anna; O'Sullivan, Joe M; Paisey, Sangeeta A; Parikh, Omi; Pudney, Delia; Ramani, Vijay; Robson, Peter; Srihari, Narayanan Nair; Tanguay, Jacob; Parmar, Mahesh K B; Sydes, Matthew R.
Afiliação
  • Parker CC; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • James ND; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Brawley CD; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Clarke NW; The Christie Hospital, Manchester, United Kingdom.
  • Ali A; Salford Royal Hospitals, Manchester, United Kingdom.
  • Amos CL; The Christie Hospital, Manchester, United Kingdom.
  • Attard G; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Chowdhury S; UCL Cancer Institute, UCL, London, United Kingdom.
  • Cook A; Guys and St Thomas's NHS Foundation Trust, London, United Kingdom.
  • Cross W; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Dearnaley DP; St James's University Hospital, Leeds, United Kingdom.
  • Douis H; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Gilbert DC; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Gilson C; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Gillessen S; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Hoyle A; Istituto Oncologico della Svizzera Italiana, EOC, Bellinzona, Switzerland.
  • Jones RJ; Università della Svizzera Italiana, Lugano, Switzerland.
  • Langley RE; The Christie Hospital, Manchester, United Kingdom.
  • Malik ZI; Salford Royal Hospitals, Manchester, United Kingdom.
  • Mason MD; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Matheson D; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Millman R; Clatterbridge Cancer Centre, Liverpool, United Kingdom.
  • Rauchenberger M; Cardiff University, Cardiff, United Kingdom.
  • Rush H; University of Wolverhampton, Wolverhampton, United Kingdom.
  • Russell JM; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Sweeney H; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Bahl A; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Birtle A; Guys and St Thomas's NHS Foundation Trust, London, United Kingdom.
  • Capaldi L; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Din O; MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
  • Ford D; University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
  • Gale J; Rosemere Cancer Centre, Lancs Teaching Hospitals, University of Manchester, Manchester, United Kingdom.
  • Henry A; UCLan, Lanchashire, United Kingdom.
  • Hoskin P; Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
  • Kagzi M; Weston Park Cancer Centre, Sheffield, United Kingdom.
  • Lydon A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • O'Sullivan JM; Queen Alexandra Hospital, Portsmouth, United Kingdom.
  • Paisey SA; University of Leeds, Leeds, United Kingdom.
  • Parikh O; The Christie Hospital, Manchester, United Kingdom.
  • Pudney D; Mount Vernon Cancer Centre, Northwood, United Kingdom.
  • Ramani V; The James Cook University Hospital, Middlesbrough, United Kingdom.
  • Robson P; Torbay and South Devon NHS Trust, Torbay, United Kingdom.
  • Srihari NN; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, United Kingdom.
  • Tanguay J; Hampshire Hospitals NHS Foundation Trust, Hampshire, United Kingdom.
  • Parmar MKB; Royal Preston Hospital, Preston, United Kingdom.
  • Sydes MR; South West Wales Cancer Centre, Swansea, United Kingdom.
PLoS Med ; 19(6): e1003998, 2022 06.
Article em En | MEDLINE | ID: mdl-35671327
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_prostate_cancer Assunto principal: Próstata / Neoplasias da Próstata Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_prostate_cancer Assunto principal: Próstata / Neoplasias da Próstata Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido